ClinicalTrials.gg
CompletedNCT02464670Updated Jun 28, 2019

Open-Label Study of INO-4212 With or Without INO-9012, Administered IM or ID Followed by Electroporation in Healthy Volunteers

A Phase 1 interventional study of INO-4201 and INO-4202 in Ebola Vaccine, sponsored by Inovio Pharmaceuticals. Completed at 3 sites in United States. Open to participants aged 18 Years to 50 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2019-06-28.

Sponsored by Inovio Pharmaceuticals · Phase 1, Interventional, and Prevention

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
240
Allocation
Randomized
Ages
18 Years to 50 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 28 studies in Hemorrhagic Fever, Ebola with a site in United States — 1 open to participants now, 2 under way, none of them phase 3. Hemorrhagic Fever, Ebola · United States.

Enrollment
6th of 27
240 · median 48
Started
2015
with 7 others
Phase 1
20 of 28
1 open now
Registered
14th of 28
by date
Lead sponsor
1 of 28
Inovio Pharmaceuticals

Among the 28 studies in Hemorrhagic Fever, Ebola with a site in United States, this one is the 6th largest by enrollment of the 27 interventional ones that give a count, is one of 8 that started in 2015, is one of 20 in phase 1, and was the 14th registered.

Hemorrhagic Fever, Ebola

104 studies on the registry are indexed under Hemorrhagic Fever, Ebola; 13 are open to participants now.

Browse Hemorrhagic Fever, Ebola studies →

Open to participants now

1 of the 28 studies in Hemorrhagic Fever, Ebola with a site in United States is open now. Recruiting first, the newest first:

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 4 Hemorrhagic Fever, Ebola studies recruiting now, 2 set no upper age limit and 2 stop at 75 or younger; none take children under 18; 4 take healthy volunteers.

This study: 18 Years to 50 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 28 studies in Hemorrhagic Fever, Ebola with a site in United States, or all of them as a file.
02

Study summary

This study evaluates whether INO-4212 and its components INO-4201 and INO-4202 administered intramuscularly (IM) or intradermally (ID) followed by electroporation (EP) will be well tolerated and immunogenic.

Read the detailed description

This study will test the safety, tolerability, and immunogenicity of the DNA vaccine, INO-4212 and its components INO-4201 and INO-4202 in healthy volunteers. INO-4201 contains the DNA sequence that codes for past Ebola Zaire virus outbreak strains, and INO-4202 contains the DNA sequence that codes for the current Ebola virus outbreak strain. When given together, the DNA vaccine is called INO-4212 and contains the DNA sequence of both the previous and the current outbreak strain. Another ingredient called INO-9012 which contains the DNA sequence for interleukin-12, will be given in a subset of subjects to help boost the body's immune response when given with the vaccine.

Following administration of vaccine, a specialized medical device, CELLECTRA®, will deliver brief electrical pulses in a process known as electroporation (EP), to help move more DNA into cells more efficiently. The study will evaluate whether INO-4212 and its components may be able to generate protective immunity against Ebola Zaire, evaluate the relative ability of IM versus ID administration to elicit immune responses and evaluate whether vaccine administered with INO-9012 can generate greater immune responses.

The Ebola vaccine under study will be tested in approximately 240 healthy adult volunteers.

03

Conditions studied

  • Ebola Vaccine

Keywords

  • Ebola
  • Vaccine
04

Who can participate

Ages eligible
18 Years to 50 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age 18-50 years;
  • Able to provide consent to participate and having signed an Form (ICF);
  • Able and willing to comply with all study procedures;
  • Women of who are in a relationship that could result in pregnancy agree to either remain sexually abstinent, use medically effective (oral contraception, barrier methods, spermicide, etc.) or have a partner who is sterile from enrollment to 3 months following the last injection; OR, sexually active men who are considered sexually fertile must agree to use either a barrier method of contraception during the study, and agree to continue the use for at least 3 months following the last injection, or have a partner who is permanently sterile or unable to become pregnant;
  • Normal screening or screening ECG with no findings;
  • Screening laboratory (Complete blood count (CBC), serum electrolytes, blood urea nitrogen (BUN), creatinine (Cr), glucose, , CPK, urinalysis) grade 0-1 within 30 days prior to administration of study treatment;
  • No history of clinically significant or disease.

Exclusion criteria

Exclusion Criteria:

  • Administration of an compound either currently or within 30 days of first dose;
  • Previous receipt of an investigational product in an interventional trial for the treatment or prevention of Ebola (exceptions: verified receipt of placebo only or participation in an observational study);
  • History of or positive serologic test for , surface antigen (HBsAg); or any potentially communicable infectious disease as determined by the Principal Investigator or Medical Monitor;
  • Positive serologic test for (exception: successful treatment with confirmation of sustained virologic response);
  • Baseline creatinine greater than 1.5 (CKD Stage II or greater);
  • Chronic liver disease or cirrhosis;
  • illness including hematologic , history of solid organ or bone marrow transplantation;
  • Any pre-excitation syndromes, e.g., Wolff-Parkinson-White syndrome;
  • Prior major surgery or radiation therapy within 4 weeks of randomization;
  • Pregnant, breast feeding, or considering becoming pregnant;
  • Less than two acceptable sites exist for intramuscular or intradermal injection and EP between use of the deltoid and lateral quadriceps muscles. A site for injection/EP is not acceptable if there are tattoos, keloids or hypertrophic scars within 2 cm of the injection/EP site.
  • Subject has significant acute or chronic medical illness if deemed by the practitioner that electroporation treatment could negatively impact the illness
  • Subject has unstable or life-threatening cardiac disease (e.g. unstable angina, class 3 or higher congestive heart failure)
  • Subject has an acute or chronic bleeding or clotting disorder that would contraindicate IM injections or use of blood thinners (e.g. anticoagulants or antiplatelet drugs) within 2 weeks;
  • Subject has a cardioverter-defibrillator or pacemaker (to prevent a life-threatening arrhythmia) that is located ipsilateral to the intended deltoid injection site (unless deemed acceptable by a Cardiologist);
  • Subject has metal implant or implantable medical device within the electroporation area;
  • Administration of any vaccine within 4 weeks of first dose;
  • Administration of any blood product within 3 months of first dose;
  • Current or anticipated concomitant immunosuppressive therapy (excluding inhaled, topical skin and/or eye drop-containing , or low-dose methotrexate). Systemic corticosteroids must be discontinued at least 4 weeks prior to first dose;
  • Current or anticipated treatment with TNF-α inhibitors such as infliximab, adalimumab, etanercept;
  • Active military service personnel;
  • Prisoner or subjects who are compulsorily detained (involuntary incarceration) for treatment of either a physical or psychiatric illness;
  • Active drug or alcohol use or dependence that, in the opinion of the investigator, would interfere with adherence to study requirements or assessment of immunologic endpoints; or
  • Any illness or condition that in the opinion of the investigator may affect the safety of the subject or the evaluation of any study endpoint.
Terms in these criteria, in plain language(14)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Phase
Phase 1
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Sequential assignment
Masking
Double (Participant, Investigator)
Enrollment
240 participants (actual)

Study arms

  • Experimental
    Group 1

    INO-4201 IM + EP, 2 mg, 3 doses

    Biological: INO-4201

  • Experimental
    Group 2

    INO-4202 IM + EP, 2 mg, 3 doses

    Biological: INO-4202

  • Experimental
    Group 3

    INO-4201 ID + EP 0.2A, 2 mg, 3 doses

    Biological: INO-4201

  • Experimental
    Group 4

    INO-4212 IM + EP, 4 mg, 3 doses

    Biological: INO-4212

  • Experimental
    Group 5

    INO-4212 + INO-9012 IM + EP, 4+1 mg, 3 doses

    Biological: INO-4212 + INO-9012

  • Experimental
    Group 6

    INO-4201 ID + EP 0.2A, 1 mg, 3 doses

    Biological: INO-4201

  • Experimental
    Group 7

    INO-4201 ID + EP 0.2A, 2 mg, 2 doses

    Biological: INO-4201

  • Experimental
    Group 8

    INO-4201 ID + EP 0.2A, 1 mg, 2 doses

    Biological: INO-4201

  • Experimental
    Group 9

    INO-4201 + INO-9012 ID + EP 0.2A, 1.6 + 0.4 mg, 3 doses

    Biological: INO-4201 + INO-9012

  • Experimental
    Group 10

    INO-4201 + INO-9012 ID + EP 0.2A, 1.6 + 0.4 mg, 2 doses

    Biological: INO-4201 + INO-9012

  • Experimental
    Group 11

    INO-4201 + INO-9012 ID + EP 0.2A, 0.8 + 0.2 mg, 3 doses

    Biological: INO-4201 + INO-9012

  • Experimental
    Part II: Group 3A

    INO-4201 ID + EP 0.2A, 2 mg, 3 doses

    Biological: INO-4201

  • Experimental
    Part II: Group 3B

    INO-4201 ID + EP 0.1A, 2 mg, 3 doses

    Biological: INO-4201

Interventions

  • BiologicalINO-4201

    INO-4201 delivered IM followed by Electroporation

  • BiologicalINO-4202

    INO-4202 delivered IM followed by Electroporation

  • BiologicalINO-4201

    INO-4201 delivered ID followed by Electroporation

  • BiologicalINO-4212

    INO-4212 delivered IM followed by Electroporation

  • BiologicalINO-4212 + INO-9012

    Drug page: Rocakinogene sifuplasmid

    INO-4212 + INO-9012 delivered IM followed by Electroporation

  • BiologicalINO-4201 + INO-9012

    Drug page: Rocakinogene sifuplasmid

    INO-4201 + INO-9012 delivered ID followed by Electroporation

06

What researchers measure

Primary outcomes

  1. Safety Assessment (Composite of multiple measures: adverse events, pain (VAS), lab abnormalities, changes in vital signs)

    Composite of multiple measures consist of: * Frequency and severity of all adverse events * Local pain immediately and at 5 and 10 minutes after Study Treatment/EP using a visual analog scale from 0 to 10, with 0 representing "No Pain" and 10 representing "Worst Pain" * Frequency and severity of local and systemic events for at least 7 days after Study Treatment/EP * Frequency and severity of laboratory abnormalities * Changes in vital signs (blood pressure, heart rate, respiratory rate, temperature)

    Time frame: Screening through up to 60 weeks following the first dose

Secondary outcomes

  1. Immunology Assessment

    Composite outcome measure consisting of multiple measures, including: * Breadth and magnitude of antigen specific ELISA * Breadth and magnitude of neutralizing antibodies * Breadth and magnitude of antigen specific cellular immune responses as determined by * Interferon-gamma (IFN-γ) ELISpot * Intracellular Cytokine Staining (CTL phenotype, Lytic granule loading, Granzyme B killing of target cells)

    Time frame: Screening and at select points up to 60 weeks following the first dose

Other outcomes

  1. Exploratory Assessment

    Composite outcome measure consisting of multiple measures, including: * Differences in immune response between ID delivery of INO-4201 followed by EP compared to IM delivery of INO-4201 followed by EP * Differences in immune response between IM delivery of INO-4212 in combination with INO-9012 followed by EP compared to IM delivery of INO-4212 alone followed by EP * Differences in immune response between ID delivery of INO-4201 in combination with INO-9012 followed by EP compared to ID delivery of INO-4201 alone followed by EP * Differences in immune response between 2 doses or 3 doses of INO-4201 alone or in combination with INO-9012 administered ID followed by EP * Differences in immune response between either 1 mg or 2mg total of INO-4201 alone or in combination with INO-9012 administered ID followed by EP * Differences in immune response between ID delivery of INO-4201 followed by EP with either 0.2 A or 0.1 A * Perception of injection among subjects enrolled in Part II

    Time frame: Screening and at select points up to 60 weeks following the first dose

07

Study locations

3 sites
  • QPS MRA
    Miami, Florida 33143, United States
  • The Center for Pharmaceutical Research
    Kansas City, Missouri 64114, United States
  • University of Pennsylvania
    Philadelphia, Pennsylvania 19104, United States
08

References and documents

Publications

  • Tebas P, Kraynyak KA, Patel A, Maslow JN, Morrow MP, Sylvester AJ, Knoblock D, Gillespie E, Amante D, Racine T, McMullan T, Jeong M, Roberts CC, Park YK, Boyer J, Broderick KE, Kobinger GP, Bagarazzi M, Weiner DB, Sardesai NY, White SM. Intradermal SynCon(R) Ebola GP DNA Vaccine Is Temperature Stable and Safely Demonstrates Cellular and Humoral Immunogenicity Advantages in Healthy Volunteers. J Infect Dis. 2019 Jul 2;220(3):400-410. doi: 10.1093/infdis/jiz132. PubMed 30891607 ↗
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of May 2015, a primary completion of May 2018 and a completion of May 2018. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
May 28, 2015
First posted
Jun 8, 2015
Start
May 2015
Primary completionActual
May 24, 2018
CompletionActual
May 24, 2018
Last update
Jun 28, 2019
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 28, 2019, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT02464670
Collaborators
GeneOne Life Science, Inc., Defense Advanced Research Projects Agency
Responsible party
Sponsor
First posted
Jun 8, 2015
Start date
May 2015
Primary completion
May 24, 2018
Completion
May 24, 2018
Last update
Jun 28, 2019

Study contacts

Scott White, MD
study director · Inovio Pharmaceuticals

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jun 2019. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Rocakinogene sifuplasmid

Start the discussion